Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biogen Idec Inc. (BIIB), Celgene Corporation (CELG), Arena Pharmaceuticals, Inc. (ARNA) & Four Bio Stocks to Buy Today

Page 1 of 2

Bio stocks can be a gamble. When they fall, companies in this particular industry can fall hard, especially if the news is really bad or expectations were hyped beyond reality. A few months ago, Peregrine Pharmaceuticals dropped 78% in one day after the company disclosed that its stellar Phase II data for lung cancer drug ‘bavituximab’ was not valid.

Does that mean bio stocks are a ‘no-go?’ Far from it, but in order to do invest effectively, one needs to remember there are a few steps you can take to increase your chances of making money and, more importantly, not losing it all after one press release hits the wires.

Spreading your bets is essential. It’s easy to be tempted to put money in just one or two names and dream of buying your own island in the Pacific after the company cures cancer. But unless you’re incredibly lucky, it doesn’t often work out that way. Picking five or even ten bio companies will reduce the damage to your portfolio should one go down as well as increase your chances of holding a winner.

Second, take the lead from big investors. Julian and Felix Baker manage money for the Tisch Family and invest primarily in biotech. One has a Ph.D. in immunology from Stanford, the other studied business at Harvard. They have had successful early positions in big winners like Seattle Genetics and Pharmasset – the latter was acquired by Gilead Sciences for $137 per share.

Finally, do your own research. Take the names that some analysts throw out and dig into the news. Here’s my top five, but again, see for yourself!

Biogen Idec Inc. (NASDAQ:BIIB)


Biogen Idec Inc. (NASDAQ:BIIB)

Biogen Idec Inc. (NASDAQ:BIIB) is an established company with solid revenue. It already has multiple sclerosis drugs that are positioned as leaders in that market. Now, its new MS pill, Tecfidera, will be priced at a wholesale acquisition cost of $54,900 per patient per year. The medicine will distributed, stocked, and available to patients this month according to company spokespeople. This is going to blow sales sky-high as people have trusted the Biogen Idec Inc. (NASDAQ:BIIB) brand. Even before this news, shares were already up over 33% so far in 2013. Biogen Idec Inc. (NASDAQ:BIIB) also has some exciting drugs in the pipeline which include a Chronic Lymphocytic Leukemia and a Non-Hodgkin’s Lymphoma in phase 3 testing. The Chronic Lymphocytic Leukemia, is dominated only by 4 companies. With Ambit Biosciences bringing in an estimated $21,000 per patient annually. Biogen Idec Inc. (NASDAQ:BIIB)’s new more effective drug would be expected to bring in this amount per patient and with the druge being more effective this will cut into their competitors market share.


Celgene Corporation (NASDAQ:CELG)

Likewise, Celgene Corporation (NASDAQ:CELG)’s Revlimid stands at the top in treating multiple myeloma and myelodysplastic syndromes. It is also counting on promising new drugs that have the potential to drive revenue even higher. Its revenue growth has slightly outpaced the industry average of 7.0%. Since the same quarter one year prior, revenue rose by 12.7%. A big drug that is in Phase 3 for Celgene Corporation (NASDAQ:CELG) is their Abraxane drug for pancreatic, metastatic melanoma, bladder, and ovarian cancers. This drug will have to compete in a market place again like Biogen Idec Inc. (NASDAQ:BIIB) with only a few competitors. With the already proven effectiveness for the drug for all of the listed cancers and the effectiveness being that on par or better than the competition we have a favorable setup. Market share will be taken with a pricing strategy to increase profits as other R&D and approval costs have already been accounted for with the release of the drug for breast cancer.

Page 1 of 2